Chengxue Dang
Overview
Explore the profile of Chengxue Dang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
108
Citations
1297
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ma Y, Sun T, Ren K, Ma R, Min T, Wang X, et al.
J Adv Res
. 2025 Feb;
PMID: 40020874
Introduction: Peritoneal adhesions cause significant morbidity due to limited therapeutic options. Current strategies are limited by inconsistent efficacy and potential side effects. Plasma-activated solutions (PAS) exhibit anti-inflammatory and healing promoting...
2.
Liu Z, Li Y, Wang S, Wang Y, Sui M, Liu J, et al.
J Exp Clin Cancer Res
. 2025 Feb;
44(1):70.
PMID: 40001243
Background: Mutations in KRAS and BRAF genes are prevalent in colorectal cancer (CRC), which strikingly promote tumorigenesis and lead to poor response to a variety of treatments including immunotherapy by...
3.
Zhang X, Liang H, Li Z, Xue Y, Wang Y, Zhou Z, et al.
Lancet Oncol
. 2025 Feb;
26(3):312-319.
PMID: 39952264
Background: The multicentre RESOLVE trial examined the efficacy of perioperative and postoperative S-1 and oxaliplatin (SOX) compared with postoperative capecitabine and oxaliplatin (CapOx) in gastric or gastro-oesophageal junction cancer. Initial...
4.
Lin J, Li W, Zhang X, Zhou K, Yang Y, Cheng S, et al.
Thromb Res
. 2024 Dec;
246():109243.
PMID: 39721224
Background: Immune checkpoint inhibitors (ICIs), which offer previously unknown therapeutic advantages, have revolutionized cancer treatment. However, the risk of thromboembolic events (TEEs) associated with ICIs remains unclear. The aim of...
5.
Li C, Tian Y, Zheng Y, Yuan F, Shi Z, Yang L, et al.
J Clin Oncol
. 2024 Oct;
43(4):464-474.
PMID: 39383487
Purpose: This multicenter, randomized phase III trial evaluated the efficacy and safety of perioperative camrelizumab (an anti-PD-1 antibody) plus low-dose rivoceranib (a VEGFR-2 inhibitor) and S-1 and oxaliplatin (SOX) (SOXRC),...
6.
Ren K, Wang X, Ma R, Chen H, Min T, Ma Y, et al.
Eur J Pharmacol
. 2024 Sep;
983:177002.
PMID: 39293571
Gastric cancer (GC) is a common malignant disease that has a fifth highest incidence and fourth highest mortality worldwide. The Warburg effect is a common phenomenon observed in tumors, which...
7.
Xu G, Meng L, Yuan D, Li K, Zhang Y, Dang C, et al.
Oncol Rep
. 2024 Aug;
52(4).
PMID: 39155871
Following the publication of this paper, it was drawn to the Editor's attention by a concerned reader that certain of the Transwell cell invasion assay data shown in Fig. 2B...
8.
Zhang X, Li W, Wang X, Lin J, Dang C, Diao D
PLoS One
. 2024 Jul;
19(7):e0306909.
PMID: 38995895
Purpose: Patients with cancer often present with a hypercoagulable state, which is closely associated with tumor progression. The purpose of this study was to assess the diagnostic efficacy of D-dimer...
9.
Hao N, Liu B, Zhao M, Lu M, Chen F, Kang J, et al.
BMC Infect Dis
. 2024 Jun;
24(1):647.
PMID: 38937679
Background: Refractory Helicobacter pylori (H. pylori) infection inevitably increase the difficulty of drug selection. Here, we described our experience with the use of a novel tetravalent IgY against H. pylori...
10.
Li W, Zhang X, Yang Y, Lin J, Zhou K, Sun R, et al.
Sci Rep
. 2024 Jun;
14(1):12758.
PMID: 38830909
Circulating tumor cells (CTCs) as a liquid biopsy have great potential in clinical applications and basic cancer research, but their clinical use in gastric cancer remains unclear. This study investigated...